Current pharmacological treatment of gastroparesis

Bibliography

• BITYUTSKIY LP, SOYKAN I, MCCALLUM RW: Viral gastroparesis: a subgroup of idiopathic gastroparesis-clinical characteristics and long-term outcomes. Am. J. Gastreenterel (1997) 92:1501–1504.
   PubMed Web of Science ®Google Scholar
• LATA PF, PIGARELLI DL: Chronic metoclopramide therapy for diabetic gastroparesis. Ann. Pharmacether: (2003) 37:122–126.
   PubMedGoogle Scholar
• ZATMAN TF, HALL JE, HARMER M:Gastric residual volume in children: a study comparing efficiency of erythromycin and metoclopramide as prokinetic agents. Br. J. Anaesth. (2001) 86:869–871.
   PubMedGoogle Scholar
• •Metodoprarnide and erythromycin produced similar gastric volumes and there was no difference in post-operative vomiting. These results indicate that erythromycin may be as effective as metoclopramide as a prokinetic agent.
   Google Scholar
• SILVERS D, KIPNES M, BROADSTONE V et al: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality of life outcomes in a multicenter controlled trial. DOM-USA-5 Study group. Clin. Ther: (1998) 20:438–453.
   Google Scholar
• •The results of this study suggest that domperidone 20 mg q.i.d. provides significant improvement in the upper gastrointestinal symptoms of diabetic gastroparesis and is well tolerated in patients with this condition.
   Google Scholar
• BRADEN B, ENGHOFER M, SCHAUB M et al.: Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment. Pharmacel Ther. (2002) 16:1341–1346.
   PubMed Web of Science ®Google Scholar
• DUTTA U, PADHY AK, AHUJA V, SHARMA MP: Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Trop. Gastreenterel (1999) 20:116–119.
   PubMedGoogle Scholar
• NARASIMHAM R, MITTAL BR, GUPTA NM: Effect of erythromycin and cisapride on emptying of the vagally denervated intrathoracic stomach. Trop. Gastreenterel (2002) 23:122–124.
   PubMedGoogle Scholar
• FRAZEE LA, MAURO LS: Eythromycin in the treatment of diabetic gastroparesis. Am. J. Ther. (1994) 1:287–295.
   PubMedGoogle Scholar
• CHEN JD, UN ZY, EDMUNDS MC 3rd, MC CALLUM RW: Effects of octeotride and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis. Dig. Dis. Sci. (1998) 43:80–89.
   PubMedGoogle Scholar
• NAKABAYASHI T, MOCHIKI E, MAMIYAMA Yet al.: Erythromycin induces pyloric relaxation accompanied by a contraction of the gastric body after pylorus-preserving gastrectomy. Surgery (2003) 133:647–655.
   Google Scholar
• ••Erythromycin can induce Phase III, in which pyloric relaxation accompanied a contraction of the gastric body in the early postoperative period after pylorus-preserving gastrectomy (PPG). Erythromycin might be used as a prokinetic agent for the treatment of early gastric stasis after PPG.
   Google Scholar
• BOIVIN MA, CAREY MC, LEVY H: Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. Pharmacetherapy (2003) 23:5–8.
   PubMed Web of Science ®Google Scholar
• ••In patients requiring intravenous erythromycin for gastric motility, a 3.0 mg/kg dose seems the most effective, with a reasonable side effect profile.
   Google Scholar
• CLANTON LJ Jr, BENDER J: Refractory spinal cord injury induced gastroparesis: resolution with erythromycin lactobionate, a case report. J. Spinal Cord Med. (1999) 22:236–238.
   PubMedGoogle Scholar
• DIBAISE JK, QUIGLEY EM: Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center's experience. Clin. Gastreenterel (1999) 28:131–134.
   PubMedGoogle Scholar
• •Prolonged administration of intravenous erythromycin in an ambulatory setting is feasible, well tolerated, and effective in patients with severe gastroparesis.
   Google Scholar
• BRAND RM, LOF J, QUIGLEY EM: Transdermal delivery of erythromycin lactobinate - implications for the therapy of gastroparesis. Alminent Pharmacel Ther. (1997) 11:589–592.
   PubMedGoogle Scholar
• •Erythromycin lactobionate, when administered transdermally, can be delivered at levels sufficient to treat gastroparesis. This technique warrants in vivo investigation.
   Google Scholar
• ISHII M, NAKAMURA T, KASAI F, BABA T, TAKEBE K: Erythromycin derivative improves gastric emptying and insulin requirement in diabetic patients with gastroparesis. Diabetes Care (1997) 20:1134–1137.
   PubMedGoogle Scholar
• COWLES VE, NELLANSHN, SEIFERT TR et al.: Effect of novel motilitide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs. Pharmacol Exp. Ther. (2000) 293:1106–1111.
   PubMedGoogle Scholar
• DHIR R, RICHTER JE: Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. Clin. Castroenterol (2004) 38:237–242.
   PubMed Web of Science ®Google Scholar
• ••Treatment of gastroparesis with low-doseerythromycin and low-bulk diet results in a dramatic short-term improvement in the majority of patients. Short-term response predicts long-term response. This response may not be as great, possibly due to tachyphylaxis.
   Google Scholar
• OEI J, LUI K: A placebo-controlled trial of low-dose erythromycin to promote feed tolerance in preterm infants. Acta Paediam (2001) 90:904–908.
   PubMedGoogle Scholar
• •Low-dose erythromycin promoted gastric emptying and feed tolerance in premature infants at a lower gestational age than previously reported. Increased exposure to broad-spectrum antibiotics may not be free of risk. Further studies are recommended to assess its efficacy in premature infants with established feed intolerance.
   Google Scholar
• EL HENNA WY AA, SPARKS JW, ARMENTROUT D, HUSEBY V, BERSETH CL: Eryhtromycin fails to improve feeding outcome in feeding-intolerant preterm infants. J. Pediam Castroenterol Num. (2003) 37:281–286.
   PubMedGoogle Scholar
• •Intragastric erythromycin does not improve feeding tolerance in preterm infants with established feeding intolerance because it fails to improve gastrointestinal function in the short- or long-term.
   Google Scholar
• MAGANTI K, ONYEMERE K, JONES MP: Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am. Castroenterol (2003) 98:259–263.
   PubMed Web of Science ®Google Scholar
• MORGANROTH J, RUEGG PC, DUNGER-BALDAUF C: Tegaserod, a 5-hydroxytryptamine Type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am. J. Castroenterol (2002) 9:2321–2327.
   Google Scholar
• BUSTI AJ, MURILLO JR Jr, CRYER B:Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy (2004) 24:526–532.
   PubMed Web of Science ®Google Scholar
• QUIGLEY EM: Acute intestinal pseudo-obstruction. Cum Treat. Options Castroenterol (2000) 3:273–286.
   PubMedGoogle Scholar
• ATHANASAKIS E, CHRYSOS E, ZORAS OJ et al.: Octeotride enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects. Aliment. Pharmacol Ther. (2002) 16:1563–1570.
   PubMedGoogle Scholar
• ROSCH W, VINSON B, SASSIN I: A randomized clinical trial comparing the efficacy of a herbal preparation STW5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Castroenertol (2002) 40:401–408.
   PubMed Web of Science ®Google Scholar
• CALBET JA, MACLEAN DA: Role of caloric content on gastric emptying in humans. J. Physiol (1997) 15:553–559.
   Google Scholar
• BECKERS EJ, JEUKENDRUP AE, BROUNS F, WAGENMAKERS AJ, SARIS WH: Gastric emptying of carbohydrate - medium chain triglyceriden suspensions at rest. hat. J. Sports Med. (1992) 13:581–584.
   Google Scholar
• VEEREMAN-WAUTERS G, STAELENS S, VAN DEN DRIESSCHE M et al.: Gastric emptying in newborns fed an intact protein formula, a partially and an extensively hydrolysed formula. Pediatr. Castroenterol Num. (2004) 39\(Suppl. 1):540.
   Google Scholar
• •Extensive hydrolysate formula empties faster than partial hydrolysate, which in turn empties faster than regular infant formula.
   Google Scholar
• TOLIA V, LIN CH, KUHNS LR: Gastric emptying using three different formulas in infants with gastroesophageal reflux. Pediam. Catsmenterol Num. (1992) 15:297–301.
   PubMedGoogle Scholar
• CALBET JA, HOLSTJJ: Gastric emptying,gastric secretion and enterogastrone reponse after administration of milk proteins or their peptide hydrolysates in humans. Eur. Num. (2004) 43:127–139.
   PubMedGoogle Scholar
• JONES MP, MAGANTI K: A systematic review of surgical therapy for gastroparesis. Am.j Castroenterol (2003) 98:2122–2129.
   PubMedGoogle Scholar
• LACY BE, ZAYAT EN, CROWELL MD, SCHUSTER MM: Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am. J. Gastroentera (2002) 97:1548–1552.
   PubMedGoogle Scholar
• EZZEDINE D, JIT R, KATZ N, GOPALSWAMY N, BHUTANI MS: Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Castrointest. Enclose. (2002) 55:920–923.
   PubMedGoogle Scholar
• UN Z, FORSTER J, SAROSIEK I, MCCALLUM RW: Treatment of diabetic gastroparesis by high-frequency gastric electrical stimulation. Diabetes Care (2004) 27:1071–1076.
   PubMedGoogle Scholar
• •In diabetic patients with refractory gastroparesis, high-frequency gastric electrical stimulation by a permanently implanted system significantly improved upper gastrointestinal symptoms, health-related quality of life, nutritional status, glucose control, and hospitalisations with an acceptably low complication rate.
   Google Scholar
• BUCKLES DC, MCCALLUM RW: Treatment of gastroparesis. Cum Treat. Options Castroenterol (2004) 7:139–147.
   PubMedGoogle Scholar
• TATEWAKI M, HARRIS M, UEMARA K: Dual effects of acupuncture on gastric motility in rats. Am J. Phsyiol. Regal Integr. Comp. Physic] (2003) 285:862–872.
   Google Scholar